PATIENT PERCEPTIONS OF DRY EYE. In a survey conducted online by Harris Interactive on behalf of Allergan among 2,411 adults, it was found that 69% of participants who experience one or more dry eye symptom(s) have not visited an ECP to treat symptoms. A majority of adults who use OTC eye drops to manage their dry eye symptoms (63%) state the OTC drops are only somewhat or not at all successful in managing their dry eye symptoms. In addition, approximately 41% adults who visited an ECP to treat their dry eye symptoms stated they visited more than once before finding relief (19%); or they still have not found relief (22%).
SLEEP DISTURBANCES AND LENS YELLOWING. Denmark’s Glostrup Hospital and Herlev Hospital conducted a study of 970 people to examine the association between lens aging (transmission and yellowing) and sleep disorders. The risk of sleep disturbances was increased when the transmission of blue light to the retina was low, even after correction for the effect of age and other factors. The study concluded that filtration of blue light by the aging lens was significantly associated with an increased risk of sleep disturbances. It was proposed this is a result of disturbance of photoentrainment of circadian rhythms.
VISUAL AND COGNITIVE STRESS. Researchers assessed 35 subjects, with 20/20 vision and without history of ocular pathology or cognitive deficits, for ocular and muscular response to long-duration reading under different visual and cognitive difficulty levels. Results showed the texts read with a refractive error caused increased orbicularis oculi EMG power and reduced aperture size. There was no statistically significant difference between conditions for pulse rate, pupil diameter, or EMG activity of the frontalis and trapezius muscles. Researchers concluded that visual stress experienced due to reading under an induced refractive error is potentially mediated by a local mechanism, different from mechanism underlying reading under low contrast or high cognitive demand.
INTRAVITREAL BEVACIZUMAB IN NEOVASCULAR AMD. Patients who received one or more intravitreal Bevacizumab injections for exudative AMD were included in a study to determine visual and anatomic outcome of intravitreal Bevacizumab injection in neovascular AMD treatment. Outcome measures included standardized visual acuity, OCT, macular thickness, IOP, and blood pressure at 24 or more weeks follow-up. The mean visual acuity was improved from 0.21 ± 0.11 before injections to 0.43 ± 0.11 after injections at six months. Overall, mean OCT macular thickness decreased by 99 micron at last follow-up. There was no incidence of severe vision loss or adverse effects.